The human alloreactive CD4+ T-cell repertoire is biased to a Th17 response and the frequency is inversely related to the number of HLA class II mismatches

Blood

Volumn 114, Issue 18, 2009, Pages 3947-3955

  Litjens, Nicolle H R ^a   Van De Wetering, Jacqueline ^a   Van Besouw, Nicole M ^a   Betjes, Michiel G H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; MINOR HISTOCOMPATIBILITY ANTIGEN; ANTINEOPLASTIC AGENT; CD40 LIGAND; IL2 PROTEIN, HUMAN; INTERLEUKIN 2;

ALLOIMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HISTOINCOMPATIBILITY; HLA MATCHING; HUMAN; HUMAN CELL; MIXED CELL CULTURE; PRIORITY JOURNAL; TH17 CELL; BLOOD DONOR; CELL CULTURE; CELL PROLIFERATION; HELPER CELL; HISTOCOMPATIBILITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; TIME;

ANTINEOPLASTIC AGENTS; BLOOD DONORS; CD40 LIGAND; CELL PROLIFERATION; CELLS, CULTURED; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS;

EID: 70449730679     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-211896     Document Type: Article

References (34)

1. Chen BP, Madrigal A, Parham P. Cytoxic T cell recognition of an endogenous class I HLA peptide presented by a HLA molecule. J Exp Med. 1990;172(3):779-788.
2. Auchincloss H Jr, Sultan H. Antigen processing and presentation in transplantation. Curr Opin Immunol. 1996;8(5):681-687.
3. Kishimoto K, Yuan X, Auchincloss H Jr, Sharpe HH, Mandelbrot DA, Sayegh MH. Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J Am Soc Nephrol. 2004;15(9):2423-2428.
4. Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today. 1999;20(2):77-82.
5. Shoji T, Wain JC, Houser SL, et al. Indirect recognition of MHC class I allopeptides accelerates lung allograft rejection in miniature swine. Am J Transplant. 2005;5(7):1626-1634.
6. Makhlouf L, Grey ST, Dong V, et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation. 2004;77(7):990-997.
7. Zhai Y, Wang Y, Wu Z, Kupiec-Weglinski JW. Defective alloreactive CD8 T cell function and memory response in allograft recipients in the absence of CD4 help. J Immunol. 2007;179(7):4529-4534.
8. Richards DM, Zhang N, Dalheimer SL, Mueller DL. Allopeptide-specific CD4(+) T cells facilitate the differentiation of directly alloreactive graft-infiltrating CD8(+) T Cells. Am J Transplant. 2007;7(10):2269-2278.
9. Roelen DL, van Bree S, van Hulst P, van Beelen E, Claas FH. Regulatory functions of human CD4(+) T cells recognizing allopeptides in the context of self-HLA class II. Hum Immunol. 2002;63(10):902-911.
10. Clarkson MR, Sayegh MH.T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation. 2005;80(5):555-563.
11. Mackey MF, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol. 1998;63(4):418-428.
12. ZhaiY, Meng L, Busuttil RW, Sayegh MH, Kupiec-Weglinski JW. Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade sensitive. J Immunol. 2003;170(6):3024-3028.
13. + T cells with diverse cytokine profiles. Nat Med. 2005;11(10):1113-1117.
14. + T cells specific for defined antigens according to CD154 expression. Nat Med. 2005;11(10):1118-1124.
15. Betjes MG, Huisman M, Weimar W, Litjens NH. Expansion of cytolytic CD4+CD28- T cells in end-stage renal disease. Kidney Int. 2008;74(6):760-767.
16. Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006;118(1):83-91.
17. Litjens NH, Huisman M, Baan CC, van Druningen CJ, Betjes MG. Hepatitis B vaccine-specific CD4(+) T cells can be detected and characterised at the single cell level: limited usefulness of dendritic cells as signal enhancers. J Immunol Methods. 2008;330(1-2):1-11.
18. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol. 1999;163(4):2267-2275.
19. Rentenaar RJ, Vosters JL, van Diepen FN, Remmerswaal EB, van Lier RA, ten Berge IJ. Differentiation of human alloreactive CD8(+) T cells in vitro. Immunology. 2002;105(3):278-285.
20. Casamayor-Palleja M, Khan M, MacLennan IC. A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J Exp Med. 1995;181(4):1293-1301.
21. Koguchi Y, Thauland TJ, Slifka MK, Parker DC. Preformed CD40 ligand exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell surface in an antigen-specific manner. Blood. 2007;110(7):2520-2527.
22. McDyer JF, Li Z, John S, Yu X, Wu CY, Ragheb JA. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol. 2002;169(5):2736-2746.
23. Snyder JT, Shen J, Azmi H, Hou J, Fowler DH, Ragheb JA. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood. 2007;109(12):5399-5406.
24. Nikolaeva N, Uss E, van Leeuwen EM, van Lier RA, ten Berge IJ. Differentiation of human alloreactive CD4+ and CD8+ T cells in vitro. Transplantation. 2004;78(6):815-824.
25. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol. 2007;7(12):942-953.
26. Williams KA, Thiel MA, Zola H. The new-generation therapeutic anti-CD25 monoclonal antibodies. Transplantation. 1999;68(9):1228-1229.
27. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517.
28. Van Kooten C, Boonstra JG, Paape ME, et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol. 1998;9(8):1526-1534.
29. Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol. 2002;197(3):322-332.
30. Woltman AM, de Haij S, Boonstra JG, Gobin SJ, Daha MR, van Kooten C. Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol. 2000;11(11):2044-2055.
31. Tang JL, Subbotin VM, Antonysamy MA, Troutt AB, Rao AS, Thomson AW. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation. 2001;72(2):348-350.
32. Kappel LW, Goldberg GL, King CG, et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009;113(4):945-952.
33. SijpkensYW, Doxiadis II, Mallat MJ, et al. Early versus late acute rejection episodes in renal transplantation. Transplantation. 2003;75(2):204-208.
34. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117:3498-3506.